Table 4. Open in new tab Patient...

	Patients with extensive necrosis (n = 10)	Patients without extensive necrosis (n = 14)
Age (years) Median (range)	62.5 (45-82)	61.5 (40-67)
Gender—no. (%) Male Female	7 (70%) 3 (30%)	12 (86%) 2 (14%)
Number of IMDC risk-factors—no. (%) Median (range)	1 (1-2)	2 (1-5)
IMDC risk—no. (%) Intermediate Poor	6 (60%) 4 (40%)	11 (79%) 3 (21%)
Histology—no. (%) Clear cell Unclassified Papillary	8 (80%) 1 (10%) 1 (10%)	11 (79%) 1 (7%) 2 (14%)
Presence sarcomatoid differentiation—no. (%)	0 (%)	3 (21%)
Type of treatment—no. (%) Pembrolizumab plus axitinib Pembrolizumab plus lenvatinib Nivolumab plus cabozantinib Ipilimumab plus nivolumab Nivolumab	4 (40%) 3 (30%) 1 (10%) 1 (10%) 1 (10%)	3 (21%) 2 (14%) 3 (21%) 3 (21%) 3 (21%)
Time ICB exposure prior to surgery (months) Median (range)	12.7 (2.11-28.8)	9.9 (3.1-42.7)
Best overall objective response to ICB—no. (%) Complete response Partial response Stable disease Progression of disease	1 (10%) 8 (80%) 1 (10%) 0 (0%)	0 (0%) 8 (57%) 6 (43%) 0 (0%)
Primary tumor size before ICB (cm) Median (range)	10.3 (5.4-17.2)	9.7 (2.8-30.0)
Pathologic tumor size (cm) Median (range)	5.7 (0-10.4)	8.2 (2.5-21.1)
Primary tumor shrink before surgery—no (%) Yes No	10 (100%) 0 (0%)	10 (71%) 4 (29%)
Necrosis extension (%) Median (range)	97.5% (95-100)	15% (0-80)
No evidence of disease after surgery—no. (%)	6 (60%)	4 (40%)
Therapy after surgery—no. (%) Surveillance Resumed same systemic therapy Switch treatment line Unavailable	7 (70%) 3 (30%) 0 (0%) 0 (0%)	6 (43%) 5 (36%) 1 (7%) 2 (14%)

Patients with
extensive necrosis
(n = 10)

Patients without
extensive necrosis
(n = 14)

Age (years)
Median (range)

62.5 (45-82)

61.5 (40-67)

Gender—no. (%)
Male
Female

7 (70%)
3 (30%)

12 (86%)
2 (14%)

Number of IMDC risk-factors—no. (%)
Median (range)

1 (1-2)

2 (1-5)

IMDC risk—no. (%)
Intermediate
Poor

6 (60%)
4 (40%)

11 (79%)
3 (21%)

Histology—no. (%)
Clear cell
Unclassified
Papillary

8 (80%)
1 (10%)
1 (10%)

11 (79%)
1 (7%)
2 (14%)

Presence sarcomatoid differentiation—no. (%)

0 (%)

3 (21%)

Type of treatment—no. (%)
Pembrolizumab plus axitinib
Pembrolizumab plus lenvatinib
Nivolumab plus cabozantinib
Ipilimumab plus nivolumab
Nivolumab

4 (40%)
3 (30%)
1 (10%)
1 (10%)
1 (10%)

3 (21%)
2 (14%)
3 (21%)
3 (21%)
3 (21%)

Time ICB exposure prior to surgery (months)
Median (range)

12.7 (2.11-28.8)

9.9 (3.1-42.7)

Best overall objective response to ICB—no. (%)
Complete response
Partial response
Stable disease
Progression of disease

1 (10%)
8 (80%)
1 (10%)
0 (0%)

0 (0%)
8 (57%)
6 (43%)
0 (0%)

Primary tumor size before ICB (cm)
Median (range)

10.3 (5.4-17.2)

9.7 (2.8-30.0)

Pathologic tumor size (cm)
Median (range)

5.7 (0-10.4)

8.2 (2.5-21.1)

Primary tumor shrink before surgery—no (%)
Yes
No

10 (100%)
0 (0%)

10 (71%)
4 (29%)

Necrosis extension (%)
Median (range)

97.5% (95-100)

15% (0-80)

No evidence of disease after surgery—no. (%)

6 (60%)

4 (40%)

Therapy after surgery—no. (%)
Surveillance
Resumed same systemic therapy
Switch treatment line
Unavailable

7 (70%)
3 (30%)
0 (0%)
0 (0%)

6 (43%)
5 (36%)
1 (7%)
2 (14%)

	Patients with extensive necrosis (n = 10)	Patients without extensive necrosis (n = 14)
Age (years) Median (range)	62.5 (45-82)	61.5 (40-67)
Gender—no. (%) Male Female	7 (70%) 3 (30%)	12 (86%) 2 (14%)
Number of IMDC risk-factors—no. (%) Median (range)	1 (1-2)	2 (1-5)
IMDC risk—no. (%) Intermediate Poor	6 (60%) 4 (40%)	11 (79%) 3 (21%)
Histology—no. (%) Clear cell Unclassified Papillary	8 (80%) 1 (10%) 1 (10%)	11 (79%) 1 (7%) 2 (14%)
Presence sarcomatoid differentiation—no. (%)	0 (%)	3 (21%)
Type of treatment—no. (%) Pembrolizumab plus axitinib Pembrolizumab plus lenvatinib Nivolumab plus cabozantinib Ipilimumab plus nivolumab Nivolumab	4 (40%) 3 (30%) 1 (10%) 1 (10%) 1 (10%)	3 (21%) 2 (14%) 3 (21%) 3 (21%) 3 (21%)
Time ICB exposure prior to surgery (months) Median (range)	12.7 (2.11-28.8)	9.9 (3.1-42.7)
Best overall objective response to ICB—no. (%) Complete response Partial response Stable disease Progression of disease	1 (10%) 8 (80%) 1 (10%) 0 (0%)	0 (0%) 8 (57%) 6 (43%) 0 (0%)
Primary tumor size before ICB (cm) Median (range)	10.3 (5.4-17.2)	9.7 (2.8-30.0)
Pathologic tumor size (cm) Median (range)	5.7 (0-10.4)	8.2 (2.5-21.1)
Primary tumor shrink before surgery—no (%) Yes No	10 (100%) 0 (0%)	10 (71%) 4 (29%)
Necrosis extension (%) Median (range)	97.5% (95-100)	15% (0-80)
No evidence of disease after surgery—no. (%)	6 (60%)	4 (40%)
Therapy after surgery—no. (%) Surveillance Resumed same systemic therapy Switch treatment line Unavailable	7 (70%) 3 (30%) 0 (0%) 0 (0%)	6 (43%) 5 (36%) 1 (7%) 2 (14%)

Table 4.

Open in new tab

Patient characteristics according to necrosis extension.

	Patients with extensive necrosis (n = 10)	Patients without extensive necrosis (n = 14)
Age (years) Median (range)	62.5 (45-82)	61.5 (40-67)
Gender—no. (%) Male Female	7 (70%) 3 (30%)	12 (86%) 2 (14%)
Number of IMDC risk-factors—no. (%) Median (range)	1 (1-2)	2 (1-5)
IMDC risk—no. (%) Intermediate Poor	6 (60%) 4 (40%)	11 (79%) 3 (21%)
Histology—no. (%) Clear cell Unclassified Papillary	8 (80%) 1 (10%) 1 (10%)	11 (79%) 1 (7%) 2 (14%)
Presence sarcomatoid differentiation—no. (%)	0 (%)	3 (21%)
Type of treatment—no. (%) Pembrolizumab plus axitinib Pembrolizumab plus lenvatinib Nivolumab plus cabozantinib Ipilimumab plus nivolumab Nivolumab	4 (40%) 3 (30%) 1 (10%) 1 (10%) 1 (10%)	3 (21%) 2 (14%) 3 (21%) 3 (21%) 3 (21%)
Time ICB exposure prior to surgery (months) Median (range)	12.7 (2.11-28.8)	9.9 (3.1-42.7)
Best overall objective response to ICB—no. (%) Complete response Partial response Stable disease Progression of disease	1 (10%) 8 (80%) 1 (10%) 0 (0%)	0 (0%) 8 (57%) 6 (43%) 0 (0%)
Primary tumor size before ICB (cm) Median (range)	10.3 (5.4-17.2)	9.7 (2.8-30.0)
Pathologic tumor size (cm) Median (range)	5.7 (0-10.4)	8.2 (2.5-21.1)
Primary tumor shrink before surgery—no (%) Yes No	10 (100%) 0 (0%)	10 (71%) 4 (29%)
Necrosis extension (%) Median (range)	97.5% (95-100)	15% (0-80)
No evidence of disease after surgery—no. (%)	6 (60%)	4 (40%)
Therapy after surgery—no. (%) Surveillance Resumed same systemic therapy Switch treatment line Unavailable	7 (70%) 3 (30%) 0 (0%) 0 (0%)	6 (43%) 5 (36%) 1 (7%) 2 (14%)

	Patients with extensive necrosis (n = 10)	Patients without extensive necrosis (n = 14)
Age (years) Median (range)	62.5 (45-82)	61.5 (40-67)
Gender—no. (%) Male Female	7 (70%) 3 (30%)	12 (86%) 2 (14%)
Number of IMDC risk-factors—no. (%) Median (range)	1 (1-2)	2 (1-5)
IMDC risk—no. (%) Intermediate Poor	6 (60%) 4 (40%)	11 (79%) 3 (21%)
Histology—no. (%) Clear cell Unclassified Papillary	8 (80%) 1 (10%) 1 (10%)	11 (79%) 1 (7%) 2 (14%)
Presence sarcomatoid differentiation—no. (%)	0 (%)	3 (21%)
Type of treatment—no. (%) Pembrolizumab plus axitinib Pembrolizumab plus lenvatinib Nivolumab plus cabozantinib Ipilimumab plus nivolumab Nivolumab	4 (40%) 3 (30%) 1 (10%) 1 (10%) 1 (10%)	3 (21%) 2 (14%) 3 (21%) 3 (21%) 3 (21%)
Time ICB exposure prior to surgery (months) Median (range)	12.7 (2.11-28.8)	9.9 (3.1-42.7)
Best overall objective response to ICB—no. (%) Complete response Partial response Stable disease Progression of disease	1 (10%) 8 (80%) 1 (10%) 0 (0%)	0 (0%) 8 (57%) 6 (43%) 0 (0%)
Primary tumor size before ICB (cm) Median (range)	10.3 (5.4-17.2)	9.7 (2.8-30.0)
Pathologic tumor size (cm) Median (range)	5.7 (0-10.4)	8.2 (2.5-21.1)
Primary tumor shrink before surgery—no (%) Yes No	10 (100%) 0 (0%)	10 (71%) 4 (29%)
Necrosis extension (%) Median (range)	97.5% (95-100)	15% (0-80)
No evidence of disease after surgery—no. (%)	6 (60%)	4 (40%)
Therapy after surgery—no. (%) Surveillance Resumed same systemic therapy Switch treatment line Unavailable	7 (70%) 3 (30%) 0 (0%) 0 (0%)	6 (43%) 5 (36%) 1 (7%) 2 (14%)

This Feature Is Available To Subscribers Only